Bolamin
Bolamin is a Khavinson short peptide bioregulator for the bone marrow. Proposed to support hematopoiesis and bone marrow stem cell function in aging. Used in anti-aging research targeting immune aging and hematopoietic reserve.
Community Rating
No ratings yet
Compound Profile
Bolamin
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Bolamin is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Proposed to support hematopoietic stem cell gene expression and bone marrow function in aging
- May complement thymic bioregulators (Thymalin, Thymagen) by addressing the bone marrow side of immune aging
- Part of comprehensive anti-aging protocols targeting the hematopoietic-immune axis
- Bolamin is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Proposed to support hematopoietic stem cell gene expression and bone marrow function in aging
- May complement thymic bioregulators (Thymalin, Thymagen) by addressing the bone marrow side of immune aging
- Part of comprehensive anti-aging protocols targeting the hematopoietic-immune axis
- Bone marrow bioregulation is proposed to support red blood cell production capacity in aging
In Plain English
Simple summaryBolamin is a synthetic tetrapeptide from the Khavinson bioregulator series targeted at bone marrow tissue and hematopoiesis. The Khavinson group proposes it restores hematopoietic stem cell gene expression in aging bone marrow, supporting the production of red blood cells, white blood cells, and platelets that declines with age. It has been studied in the context of age-related hematopoietic decline, post-radiation bone marrow recovery, and as a supportive therapy during cancer treatment-related cytopenias in Russian clinical settings.
- Proposed to support hematopoietic stem cell gene expression and bone marrow function in aging
- May complement thymic bioregulators (Thymalin, Thymagen) by addressing the bone marrow side of immune aging
- Part of comprehensive anti-aging protocols targeting the hematopoietic-immune axis
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Bolamin?
Tap any underlined term for an instant definition.
Bolamin is a peptide bioregulator developed by Professor Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, derived from bone marrow tissue. It is designed to target hematopoietic aging — the age-related decline in bone marrow stem cell number, function, and output.
In the Khavinson bioregulator framework, each organ has a corresponding short regulatory peptide that can help maintain or restore youthful gene expression patterns in that organ's cells. Bolamin represents the bone marrow/hematopoietic tissue in this system, complementing thymic preparations (Thymalin, Thymagen) which target T-lymphocyte development in the thymus.
The bone marrow and thymus together constitute the primary lymphoid organs — where lymphocytes are born (marrow) and educated (thymus). Aging is associated with
- Reduced hematopoietic stem cell (HSC) self-renewal capacity
- Shift from lymphopoiesis toward myelopoiesis in aging HSCs (which may contribute to immune aging)
- Reduced erythropoietic reserve
- Declining immune reconstitution capacity
Bolamin is proposed to address the marrow side of this equation. It is often used in comprehensive anti-aging protocols alongside Thymalin (thymus), Epithalon (pineal), Cartalax (cartilage), and Vesugen (vascular) as part of the multi-organ bioregulator approach.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Bolamin. See all Muscle & Performance peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Oral capsule. Part of the Khavinson Institute organ-targeted bioregulator system.
What the research doesn't show
Bolamin represents the most ambitious claim in the Khavinson series -- restoring bone marrow hematopoietic function is a complex challenge that established biologic drugs (EPO, G-CSF, thrombopoietin analogues) address with extensive clinical evidence. The idea that a short tetrapeptide specifically restores hematopoietic stem cell gene expression through topical or oral delivery faces significant mechanistic skepticism.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Bolamin, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Bolamin has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: proposed to support hematopoietic stem cell gene expression and bone marrow function in aging.
The most commonly reported side effect in research subjects is minimal adverse effects reported in the khavinson research program context. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Erythropoietin (EPO) and G-CSF are the established hematopoietic growth factors used clinically for anemia and neutropenia with massive trial evidence. ARA-290 is derived from erythropoietin but targets tissue protection rather than red cell production. Romiplostim and eltrombopag are approved thrombopoietin receptor agonists for platelet production. Bolamin's proposed hematopoietic support has vastly less evidence than any of these approved agents.
Compare Bolamin side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.